GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock?

It'd be a mistake to overlook these stocks, despite their recent challenges.

Intuitive Surgical's ISRG single-port (SP) platform emerges as one of its most intriguing long-term growth opportunities, though the key question remains whether it can unlock incremental total addressable market (TAM) or simply serve as a substitution within existing robotic procedures.

Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

Everyone is still glued to Tesla (NASDAQ:TSLA | TSLA Price Prediction) because a Q1 earnings beat, the robotaxi pitch, and the Optimus humanoid tease have convinced retail traders the autonomy story finally pays off this year.

Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics.

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.